ZOMDF (Zomedica) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is Zomedica Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Zomedica's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ZOMDF vs RPID, STIM, OM: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Zomedica's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zomedica Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Zomedica's Margin of Safety % (DCF Earnings Based) falls into.


Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.